Automated CT-based analysis to detect changes in the prevalence of lytic bone metastases from breast cancer

被引:13
作者
Skrinskas, T. [1 ]
Clemons, M. [2 ]
Freedman, O.
Weller, I.
Whyne, C. M. [1 ]
机构
[1] Sunnybrook Hlth Sci Ctr, Div Orthopaed Surg, Bone Metastases Grp, Orthopaed Biomech Lab, Toronto, ON M4N 3M5, Canada
[2] Univ Toronto, Princess Margaret Hosp, Div Med Oncol, Toronto, ON M5G 2M9, Canada
关键词
Spinal metastasis; Breast cancer; CT; Osteolytic; Osteoblastic; Bisphosphonates; QUANTITATIVE CHARACTERIZATION; AMERICAN SOCIETY; BISPHOSPHONATES; CARCINOMA; DISEASE; PAMIDRONATE; SURVIVAL; SPINE; WOMEN;
D O I
10.1007/s10585-008-9219-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The spinal column is the most frequent site of bone metastasis in patients with breast cancer. It is important to understand how the pattern of vertebral lesions may be affected by the introduction of modern cancer therapies. The purpose of this study was to characterize changes in the radiological appearance of spinal column metastases over the past decade using highly automated Computed Tomography (CT) based computational analysis methods. Two case series studies were performed using CT scans of patients with confirmed spinal metastases secondary to breast cancer: Cohort A with CT scans acquired between 1998 and 2001 and Cohort B with CT scans acquired between 2004 and 2007. Diseased vertebrae were classified as lytic, blastic, or mixed based on CT scan intensity through an automated 3D computer algorithm. The relative incidence of lytic vertebral metastases decreased in comparing Cohort B to Cohort A (12% vs. 49%) with a corresponding increase in mixed lesions (51% vs. 18%) Significant associations were found between the percentage of lytic lesions in number of diseased vertebrae measured per patient and lack of bisphosphonate use (RR = 2.6) and for membership in Cohort A vs. Cohort B (RR = 5.9). This work highlights a change in the CT appearance of vertebral metastases from breast cancer during the past decade toward a lower proportion of lytic disease. Observation of patient therapies suggests that differences in radiological assessment may be linked, at least in part, to bisphosphonate use. These findings have important implications for both clinical practice and research strategies involving vertebral metastases.
引用
收藏
页码:97 / 103
页数:7
相关论文
共 29 条
  • [1] ABRAMS HL, 1950, CANCER, V3, P74, DOI 10.1002/1097-0142(1950)3:1<74::AID-CNCR2820030111>3.0.CO
  • [2] 2-7
  • [3] Belhaj Raja, 2002, Tunis Med, V80, P691
  • [4] *BREAST CANC DIS S, 2003, US BISPH PAT BON MET
  • [5] SECONDARY MALIGNANT DISEASE OF BONE
    CLAIN, A
    [J]. BRITISH JOURNAL OF CANCER, 1965, 19 (01) : 15 - &
  • [6] Clinical features of metastatic bone disease and risk of skeletal morbidity
    Coleman, Robert E.
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (20) : 6243S - 6249S
  • [7] CARCINOMATOUS METASTASIS TO VERTEBRAL BODIES
    DRURY, RAB
    HIGHMAN, WJ
    PALMER, PH
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 1964, 17 (04) : 448 - &
  • [8] Recent developments in bisphosphonates for patients with metastatic breast cancer
    Gainford, MC
    Dranitsaris, G
    Clemons, M
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7494): : 769 - 773
  • [9] Guise Theresa A., 2000, Cancer, V88, P2892, DOI 10.1002/1097-0142(20000615)88:12+<2892::AID-CNCR2>3.0.CO
  • [10] 2-Y